Skip to main content
. 2021 Dec 23;399(10321):237–248. doi: 10.1016/S0140-6736(21)02753-7

Figure 2.

Figure 2

Cumulative incidence of COVID-19 with onset at least 1-day postvaccination with either Ad5-nCoV or placebo

Cases were all PCR-confirmed cases, adjudicated by the independent endpoint review committee. Ad5-nCoV=adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein.